IFF outlines a disciplined reinvestment strategy after divestiture, targeting 5-6% of sales in capex (closer to 6% in 1-2 years) and sustaining R&D around 8-9%, with 2026 free cash flow expected to rise despite near-term working-capital headwinds.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
What did management say about Capex and reinvestment post-divestiture?
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
Post-divestiture, IFF plans Capex around 5-6% of sales, with the upper end near 6% in the next 1-2 years to fund high-return initiatives, while keeping reinvestment and R&D at 8-9% of sales to support growth. Near-term cash-flow timing headwinds from the divestiture are expected, but full-year 2026 free cash flow should exceed 2025.
Sources used
Research questionWhat did management say about Capex and reinvestment post-divestiture?
Answer outline
Post-divestiture, IFF outlines a Capex target of 5-6% of sales and an emphasis on sustaining reinvestment, notably in innovation. Management ties R&D at 8-9% of sales to a growth-and-margin expansion cycle, while acknowledging temporary stranded costs and working-capital headwinds from the separation.
Sources used
Research questionWhat did management say about Capex and reinvestment post-divestiture?
Answer outline
IFF's Q2 2026 earnings discussion highlights post-divestiture Capex guidance of about 5-6% of sales, with a tilt toward 6% over the next 1–2 years as high-return initiatives advance. Management ties reinvestment, including R&D at roughly 9% of sales, to growth and margin expansion while prioritizing organic scaling and bolt-ons for Remainco.
Sources used
Research questionWhat did management say about Capex and reinvestment post-divestiture?
Answer outline
Post-divestiture, IFF outlines a reinvestment-led transformation plan. Capex is targeted at roughly 5–6% of sales, with a tilt toward the 6% range in the next 1–2 years to fund high-return, innovation-driven initiatives. R&D sits around 9% of sales. Near-term cash flow effects are driven more by working capital than capex policy, and the portfolio is viewed as set after the Food Ingredients divestiture.
Sources used
Research questionWhat did management say about Capex and reinvestment post-divestiture?
Answer outline
Post-divestiture, IFF signals a 5-6% capex run-rate (likely near 6% in the next 1-2 years) alongside 8-9% of sales in R&D, tying reinvestment to Remainco growth and margin expansion. Management also expects cash-flow improvements over time as the divestiture optimizes the capital mix.
Sources used
Research questionWhat did management say about Capex and reinvestment post-divestiture?
Answer outline
IFF outlines a disciplined post-divestiture reinvestment plan, targeting CapEx at 5-6% of sales and R&D at 8-9%, to differentiate the business and drive margin expansion. Despite near-term working capital headwinds, management expects 2026 free cash flow to exceed 2025, enabling continued reinvestment.
Sources used
Research questionWhat did management say about Capex and reinvestment post-divestiture?
Answer outline
Post-divestiture, IFF signals a Capex target of 5-6% of sales, with near-term leaning toward ~6% to fund high-return initiatives. Reinvestment is anchored in R&D/innovation for the Remainco, with R&D running around 8-9% of sales and potential increases as sales grow.
Sources used
Research questionWhat did management say about Capex and reinvestment post-divestiture?
Answer outline
IFF outlines post-divestiture Capex targets of roughly 5-6% of sales, with near-term guidance near the upper end to fund high-return initiatives, while prioritizing R&D reinvestment to support the Remainco growth and margin expansion. The discussion also covers stranded costs, cash-flow framing, and near-term working-capital headwinds tied to the divestiture.
Sources used
Research questionWhat did management say about Capex and reinvestment post-divestiture?
Answer outline
IFF outlines a Scent recovery anchored in disciplined reinvestment in R&D, a strengthened pipeline, and careful navigation of Middle East volatility, with 2H 2026 expected growth in Fine Fragrance and a normalization to low single digits in Consumer Fragrance. The multi-year R&D plan targets 2027 by advancing molecules, delivery systems, and leading‑edge perfumers to sustain competitive advantage.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF frames Scent's recovery around a rebuilt, stronger R&D pipeline and innovative delivery systems, with Fragrance Ingredients accelerating on higher-value inputs. For H2, Fine Fragrance should see a softer Q3 followed by a stronger Q4, while Consumer Fragrance is expected to grow in the low single digits as R&D and go-to-market efforts support market-share gains—backed by an ongoing 8-9% R&D investment to fuel 2027 growth.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Post-divestiture, IFF signals a disciplined capital allocation plan focused on a 5%-6% Capex target, with a near-term tilt toward 6%. It also emphasizes sustained R&D investment (about 8%-9% of sales, now around 9%) to drive growth and margin expansion.
Sources used
Research questionWhat did management say about Capex and reinvestment post-divestiture?
Answer outline
IFF's Scent recovery hinges on a rebuilt R&D engine, stronger go-to-market execution, and resilient Fine Fragrance performance amid regional volatility. In H2, Fine Fragrance is expected to deliver mid-single-digit growth with a soft Q3 and stronger Q4, while Consumer Fragrance normalizes to low single-digit gains; the company reiterates a 2027-focused plan to sustain innovation through heightened R&D investment and a robust molecule and delivery-systems pipeline.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Dafinchi